ClinicalTrials.gg
Enrolling by invitationNCT06683118Updated Nov 12, 2024

Registration Trial of the Drug-coated Balloon for the Symptomatic Cerebral Atherosclerotic Stenosis

An interventional study of Rapamycin neurovascular Balloon Catheter and Conventional Balloon in Cerebral Atherosclerotic Stenosis, sponsored by MicroPort NeuroTech Co., Ltd.. Enrolling by invitation at 2 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-11-12.

Sponsored by MicroPort NeuroTech Co., Ltd. (formerly part of MicroPort Scientific Corporation) · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2025, 1 year 3 months ago, but the record still lists the study as enrolling by invitation.
  • Registered 5 months after the study started (first participant enrolled May 2024, registered Nov 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
212
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 81 studies in Constriction, Pathologic with a site in China — 37 open to participants now, 40 under way, 3 of them phase 3. Constriction, Pathologic · China.

Planned enrollment
20th of 56
212 · median 145
Started
2024
with 11 others
No phase
48 of 81
21 open now
Primary completion
2025-07
later than 6 of 39 live
Registered
61st of 81
by date

Among the 81 studies in Constriction, Pathologic with a site in China, this one is the 20th largest by planned enrollment of the 56 interventional ones that give a count, is one of 12 that started in 2024, is one of 48 with no phase, reaches primary completion later than 6 of the 39 other live ones, and was the 61st registered.

Constriction, Pathologic

457 studies on the registry are indexed under Constriction, Pathologic; 110 are open to participants now.

Browse Constriction, Pathologic studies →

Open to participants now

37 of the 81 studies in Constriction, Pathologic with a site in China are open now. Recruiting first, the newest first:

32 more — sign in →

All 37 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 67 Constriction, Pathologic studies recruiting now, 34 (51%) set no upper age limit and 14 (21%) stop at 75 or younger; 8 take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in Constriction, Pathologic with a site in China, or all of them as a file.
02

Study summary

The purpose of the trail is to determine whether DCB is superior to conventional balloon in treating cerebral atherosclerotic stenosis

03

Conditions studied

  • Cerebral Atherosclerotic Stenosis
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Incsion Criteria:

  • Age 18 to 80 years old at signing.
  • Symptomatic atherosclerotic stenosis of cerebrovascular arteries with ≥70% stenosis.
  • Medication ineffective.
  • modified Rankin Scale(mRS) score≤2.
  • The subject or guardian is able to understand the purpose of the study, is willing to participate and has given written informed consent.

Exclusion Criteria:

  • History of acute ischemic stroke within 2 weeks;
  • Stenosis due to non-atherosclerotic lesions such as arterial dissection, Moya-Moya disease and vasculitic disease;
  • Target vessels complete occlusion or with thrombus in target vessels;
  • Target vessel with severe calcification or distortion that making interventional device is difficult to place;
  • History of stenting in the target artery;
  • Target vessel restenosis following stenting or balloon angioplasty;
  • Combined with other lesion with ≥70% stenosis in target vessel.
  • Residual stenosis ≥50% or vessel dissection with obvious blood flow restriction occurs after predilation.
  • Combined with intracranial tumour, arteriovenous malformation or aneurysm of the target vessel.
  • History of intracranial hemorrhage within 90days.
  • Presence of severe systemic diseases that cannot tolerate surgery, such as severe liver and kidney dysfunction;
  • to the use of anticoagulants and antiplatelet agents, such as sllergy to anticoagulants and antiplatelet agents, active bleeding or coagulation disorders;
  • Allergic to contrast agents or rapamycin;
  • Pregnant or lactating women;
  • Participating or intending to participate in any other drug/device clinical trials;
  • \<1 year;
  • Any other conditions that the investigator deems the patient unsuitable for enrollment.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
212 participants (estimated)

Study arms

  • Experimental
    experimental group

    Device: Rapamycin neurovascular Balloon Catheter

  • Active comparator
    control group

    Device: Conventional Balloon

Interventions

  • DeviceRapamycin neurovascular Balloon Catheter

    Drug-coated balloon for the symptomatic cerebral atherosclerotic stenosis

  • DeviceConventional Balloon

    Conventional Balloon for the symptomatic cerebral atherosclerotic stenosis

06

What researchers measure

Primary outcomes

  1. Target lesion restenosis rate at 6 month postoperative

    The primary endpoint was the restenosis rate at 6 month postoperatively. Restenosis was defined as ≥50% measured stenosis of the target lesion by imaging according to WASID method.

    Time frame: 180±30days

Secondary outcomes

  1. Technical succeed rate

    defined as smooth delivery of the device to the target lesion and successful dilatation, unloading, and retraction

    Time frame: Intraoperation

  2. Target vascular-related stroke or death at 30 days postoperatively

    Time frame: 30±7days

  3. Any stroke or death at 30 days postoperatively

    Time frame: 30±7days

  4. Target vascular-related stroke or death at 6 month postoperatively

    Time frame: 180±30days

  5. Any stroke or death at 6 month postoperatively

    Time frame: 180±30days

  6. Target vascular-related stroke or death at 12 month postoperatively

    Time frame: 360±60days

  7. Any stroke or death at 12 month postoperatively

    Time frame: 360±60days

07

Study locations

2 sites
  • Tiantan Hospital Affiliated of Peking University
    Beijing, Beijing, China
  • Huashan Hospital Affiliated of Fudan University
    Shanghai, Shanghai, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Jul 2025, 14 months after the start.

Of 43 industry-sponsored interventional studies with no phase under Constriction, Pathologic, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 58. This study's planned 14 months is below that.

Counting every sponsor, half of 133 studies reached it within 36 months; a quarter within 18 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2024
First posted
Nov 12, 2024
StartActual
May 27, 2024
Primary completionEst.
Jul 27, 2025
CompletionEst.
Jul 27, 2026
Last update
Nov 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06683118
Responsible party
Sponsor
First posted
Nov 12, 2024
Start date
May 27, 2024
Primary completion
Jul 27, 2025 (estimated)
Completion
Jul 27, 2026 (estimated)
Last update
Nov 12, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion